SCHEMBL4051577

SCHEMBL4051577

COc1cccc(-c2nc3cc(-c4ccccc4)ccc3o2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.74
▸ HPGD P15428 5/20 0.74
▸ TP53 P04637 5/20 0.74
▸ RAB9A P51151 5/20 0.74
▸ NPC1 O15118 5/20 0.74
▸ ALDH1A1 P00352 4/20 0.74
▸ HSD17B10 Q99714 4/20 0.74
▸ L3MBTL1 Q9Y468 3/20 0.74
▸ NFKB1 P19838 3/20 0.74
▸ NFKB2 Q00653 3/20 0.74
▸ RELA Q04206 3/20 0.74
▸ KDM4E B2RXH2 3/20 0.74
▸ TDP1 Q9NUW8 2/20 0.74
▸ GLA P06280 1/20 0.74
▸ F2 P00734 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ FAAH O00519 1/20 0.60
▸ UTRN P46939 1/20 0.60
▸ PTPN2 P17706 3/20 0.57
▸ PTPN1 P18031 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059683 0.89 NPC1 (0.65) SMN1; SMN2HPGDTP53RAB9ANPC1
SCHEMBL28612592 0.89 PTPN2 (0.62) SMN1; SMN2HPGDTP53RAB9ANPC1
SCHEMBL4062301 0.86 NPC1 (0.66) SMN1; SMN2HPGDTP53RAB9ANPC1
SCHEMBL592290 0.86 ALDH1A1 (0.72) SMN1; SMN2HPGDTP53RAB9ANPC1
SCHEMBL5834333 0.85 NPC1 (0.65) SMN1; SMN2HPGDTP53RAB9ANPC1
SCHEMBL4052671 0.85 NPC1 (0.62) SMN1; SMN2HPGDTP53RAB9ANPC1
SCHEMBL4057106 0.85 ALDH1A1 (0.67) SMN1; SMN2HPGDTP53RAB9ANPC1
SCHEMBL4052772 0.85 NPC1 (0.69) SMN1; SMN2HPGDTP53RAB9ANPC1
SCHEMBL12639231 0.84 RAB9A (0.74) SMN1; SMN2HPGDTP53RAB9ANPC1
SCHEMBL28559369 0.84 SMN1; SMN2 (0.66) SMN1; SMN2HPGDTP53RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 — — US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 — — US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 — — US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 — — US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B SMN1; SMN2 4289/4885HPGD 3915/4885TP53 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback